Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2018

View Archived Issues

SRC-3 shushes stem cells

Misfolded tau proteins differ by tauopathy

Novartis describes profile of promising BTK inhibitor LOU-064

BAY-1101042, a potent NO- and heme-independent sGC activator suitable for oral dosing

Selective nonlethal mechanism-based inhibitors of gut microbial TMAO reduce thrombosis potential

Medications for alcohol or opioid use disorders may reduce suicidal behavior and criminality

New phase I trial evaluates Inovio's GLS-6150 to prevent hepatitis C

OPKO Health announces initiation of phase II study of Rayaldee in dialysis patients

Additional positive data presented from phase IIa study of NasoVAX intranasal influenza vaccine

Boehringer Ingelheim and Tsinghua University to develop novel therapies against infectious diseases

Nerlynx approved in Europe as extended adjuvant therapy of HER2-positive early-stage breast cancer

Positive results reported across multiple endpoints in ZENITH-1 trial of oral BCX-7353

Ossianix to use BBB delivery technology with agents from Novo Nordisk

Development of a new PDE9A inhibitor for the treatment of CNS diseases

National Institute of Pharmaceutical R&D divulges BTK ihibitors

Palobiofarma and Novartis patent adenosine A2A receptor antagonists

FDA grants IND clearance for phase II/III study of LYS-SAF-302 for MPS IIIA

Galderma Research & Development discloses RORC inverse agonists

Oryzon Genomics identifies new lysine-specific demethylase inhibitors

Tesaro advances JASPER study of Zejula in NSCLC

Turnstone Biologics and La Jolla Institute collaborate to develop new cancer immunotherapies

Elunate approved in China for colorectal cancer

Pieris initiates phase I trial of PRS-343 plus atezolizumab in HER2-positive solid tumors

New PARP-1 inhibitor presented for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...